Rain Therapeutics Stock Price

0.00 (0.0%)
Volume 7
Bid Price 4.35
Ask Price 5.40
News -
Day High


52 Week Range


Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Rain Therapeutics Inc RAIN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 4.85 07:01:15
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
2 7 - 2.15 - 22.22
Last Trade Time Type Quantity Stock Price Currency
07:01:52 6 $ 4.85 USD


Draw Mode:

Rain Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 128.67M 26.53M 6.51M $ - $ - -2.04 -2.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 14.20%

more financials information »

Rain Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RAIN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week4.836.204.36015.33317,1370.020.41%
1 Month3.,2351.8260.07%
3 Months4.356.202.153.66222,8720.5011.49%
6 Months12.3113.2192.154.92139,902-7.46-60.6%
1 Year17.9322.222.158.46104,634-13.08-72.95%
3 Years22.1023.902.1511.42133,893-17.25-78.05%
5 Years22.1023.902.1511.42133,893-17.25-78.05%

Rain Therapeutics Description

Rain Therapeutics Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Your Recent History
Rain Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220707 11:17:31